NCT05678881View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 25, 2022

Primary Completion Date

February 23, 2024

Study Completion Date

February 23, 2024

Conditions
Epilepsy
Interventions
DRUG

High dose RLS103

8 mg CBD inhaled powder

DRUG

placebo inhaled powder

placebo inhaled powder

DRUG

Low dose RLS103

4 mg CBD inhaled powder (open label)

Sponsors
All Listed Sponsors
collaborator

The Epilepsy Study Consortium

OTHER

lead

Receptor Life Sciences

INDUSTRY